In a report released yesterday, Richard Newitter from Truist Financial maintained a Buy rating on Irhythm Technologies (IRTC – Research Report), with a price target of $145.00. The company’s shares closed yesterday at $117.98.
Newitter covers the Healthcare sector, focusing on stocks such as Stryker, Nevro Corp, and Inspire Medical Systems. According to TipRanks, Newitter has an average return of 17.3% and a 59.89% success rate on recommended stocks.
Irhythm Technologies has an analyst consensus of Strong Buy, with a price target consensus of $127.60.
See today’s best-performing stocks on TipRanks >>
Based on Irhythm Technologies’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $124.6 million and a GAAP net loss of $27.12 million. In comparison, last year the company earned a revenue of $103.88 million and had a GAAP net loss of $21.45 million
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRTC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Irhythm Technologies (IRTC) Company Description:
iRhythm Technologies, Inc. is a commercial-stage digital healthcare company, which engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers ZIO which diagnose many arrhythmias, avoiding multiple indeterminate tests, allowing for appropriate medical intervention, and prevents serious downstream medical events. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.
Read More on IRTC:
- iRhythm reports closing of five-year debt facility
- iRhythm says grew Q4 patient registrations in excess of 22% y/y
- iRhythm Technologies Shares Preliminary Fourth Quarter 2023 Highlights and Business Update at the 42nd Annual J.P. Morgan Healthcare Conference
- iRhythm sees FY24 revenue $575M-$585M, consensus $578.72M
- iRhythm announces results from CAMELOT study have been published
